We are live on ! Find out more

Neuropace

NPCE

Market cap $429M

12.50 USD

-0.19

1.5%

At close Updated Nov 6, 4:00 PM EST

Pre-market

After hours

12.50

0.00

0%

1 day

-1.5%

5 days

0%

1 month

-1.34%

3 months

-10.07%

6 months

-31.02%

Year to date

-17.6%

1 year

-2.19%

5 years

-26.25%

10 years

-49.92%

About: NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures. The company offers the RNS System, a brain-responsive neuromodulation system that continuously monitors and analyzes the brain's electrical activity and delivers personalized, real-time electrical pulses at the seizure source to prevent seizures. The RNS System includes the RNS neurostimulator, cortical strip leads, depth leads, a Patient Remote Monitor, and other implantable and non-implantable accessories used during implant procedures. The company also provides the Physician Tablet, Patient Data Management System, and the nSight Platform to facilitate ongoing patient monitoring and support clinicians in managing patient care.

Employees: 220

Healthcare Medical Devices

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 30.8%

Neutral 53.8%

Negative 15.4%

NeuroPace to Report Third Quarter 2026 Financial Results on November 12, 2026

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the third quarter of 2026 after market close on Thursday, November 12, 2026. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).Investors interested in listening to the conference call may do so by access.

NeuroPace to Report Third Quarter 2026 Financial Results on November 12, 2026

Zacks Investment Research

Why Is NeuroPace (NPCE) Down 0.4% Since Last Earnings Report?

NeuroPace (NPCE) reported earnings 30 days ago. What's next for the stock?

Why Is NeuroPace (NPCE) Down 0.4% Since Last Earnings Report?

Zacks Investment Research

Here's Why You Should Retain NeuroPace Stock in Your Portfolio for Now

NPCE's RNS adoption, reimbursement gains, referral expansion and AI tools support growth, while IGE delays and higher spending pressure profitability.

Here's Why You Should Retain NeuroPace Stock in Your Portfolio for Now

NeuroPace to Participate in 2026 Cantor Global Healthcare Conference

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will participate in the upcoming 2026 Cantor Global Healthcare Conference. NeuroPace management will participate in a fireside chat discussion on Wednesday, September 9 at 10:55am EDT, and host one-on-one meetings with investors during the conference. The fireside chat will be accessible via a.

NeuroPace to Participate in 2026 Cantor Global Healthcare Conference

NeuroPace to Participate in Wells Fargo 21st Annual Healthcare Conference

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will participate in the upcoming Wells Fargo 21st Annual Healthcare Conference. NeuroPace management will participate in a fireside chat discussion on Tuesday, September 8 at 8:00am EDT, and host one-on-one meetings with investors during the conference. The fireside chat will be accessible via.

NeuroPace to Participate in Wells Fargo 21st Annual Healthcare Conference

Zacks Investment Research

NeuroPace Faces an IGE Delay: What the FDA Setback Means for Growth

NPCE's IGE expansion faces a regulatory delay, shifting focus to rising RNS adoption as the company works through the FDA review process.

NeuroPace Faces an IGE Delay: What the FDA Setback Means for Growth

Zacks Investment Research

Is NeuroPace a Buy as Growth Improves but Valuation Stays Elevated?

NPCE's stronger RNS adoption, narrowing losses and AI expansion support growth, but premium valuation, liquidity and regulatory risks warrant patience.

Is NeuroPace a Buy as Growth Improves but Valuation Stays Elevated?

Zacks Investment Research

NPCE Is Down 12.7% in 3 Months: Is the Pullback a Buying Opportunity?

NeuroPace's stronger RNS growth, raised 2026 guidance and AI expansion face a less certain IGE regulatory path after the FDA setback.

NPCE Is Down 12.7% in 3 Months: Is the Pullback a Buying Opportunity?

NeuroPace, Inc. (NPCE) Q2 2026 Earnings Call Transcript

NeuroPace, Inc. (NPCE) Q2 2026 Earnings Call Transcript

NeuroPace, Inc. (NPCE) Q2 2026 Earnings Call Transcript

Zacks Investment Research

NPCE Q2 Earnings Beat Estimates on RNS Growth, '26 Revenue View Up

NeuroPace's Q2 revenues rise 17.1% as RNS demand strengthens, while a narrower loss and higher 2026 outlook highlight continued momentum.

NPCE Q2 Earnings Beat Estimates on RNS Growth, '26 Revenue View Up

See News Rankings

Price charts implemented using Lightweight Charts™